Triamcinolone Therapy Guidelines

Dermatologic Indications

The American Academy of Dermatology recommends using intralesional triamcinolone acetonide for inflammatory nodulocystic acne and acne keloidalis, with a dose of 10 mg/mL (may be diluted to 5 or 3.3 mg/mL with sterile normal saline) directly into nodular acne lesions 1
For acne keloidalis, the American Academy of Dermatology suggests injecting triamcinolone acetonide into inflammatory follicular lesions, and for hypertrophic scars and keloids, using triamcinolone acetonide -40 1
Intralesional triamcinolone is efficacious for occasional or particularly stubborn cystic lesions but is not an effective strategy for patients with multiple lesions, according to the American Academy of Dermatology 1
The American Academy of Dermatology notes that this treatment flattens most acne nodules within 48 to 72 hours 1
For recurrent lesions in children, the American Academy of Dermatology considers intralesional triamcinolone hexacetonide (5-10 mg/mL) over triamcinolone acetonide, as it provides more complete and longer duration of clinical response 2

The American College of Rheumatology strongly recommends intra-articular glucocorticoids as part of initial therapy for active oligoarthritis, with triamcinolone hexacetonide being the preferred choice over triamcinolone acetonide for intra-articular injections in juvenile idiopathic arthritis (JIA) 3, 4, 5, 6
The American College of Rheumatology suggests using intra-articular glucocorticoids as adjunct therapy in polyarticular JIA when arthritis is preventing ambulation or interfering with important daily activities 5, 6
For acute gout involving 1-2 large joints, the American College of Rheumatology recommends using intra-articular corticosteroids as an appropriate option, with the dose based on the size of the involved joint(s) 7
The American College of Rheumatology notes that among intra-articular corticosteroids, triamcinolone hexacetonide is the most effective for relieving local symptoms of inflammation in early rheumatoid arthritis 8

The American Academy of Dermatology advises against injecting at sites of active infections such as impetigo or herpes, and avoiding use in patients with previous hypersensitivity to triamcinolone, active tuberculosis or systemic fungal infection, extensive plaque psoriasis, pustular psoriasis, or erythrodermic psoriasis, active peptic ulcer disease, uncontrolled diabetes, heart failure, or severe hypertension, and severe depression or psychosis 1, 9

The American Academy of Dermatology warns that local overdose of intralesional triamcinolone can result in atrophy, pigmentary changes, telangiectasias, and hypertrichosis, and repeated injections can suppress the hypothalamic-pituitary-adrenal axis, with monitoring recommended for infections, impaired wound healing, sterile abscess, and steroid acne 1, 9
The American Academy of Pediatrics advises against long-term continuous use of triamcinolone in children due to risk of skin atrophy, growth suppression, and HPA axis suppression, and recommends using the minimum effective amount and considering periodic breaks in treatment 2